Not sure what the rules are around here regarding drug discussion...but if anyone knows someone who's addicted to alcohol or opiates and has an underlying desire to get clean, psychedelics like Ibogaine and Psilocybin can seriously help.
Psilocybin helped me end 5 years of poly drug abuse in 2009. I've been clean for almost 13 years now. This is anecdotal but if you browse Reddit drug-related subreddits like /r/Drugs and /r/Shrooms you'll find plenty of similar stories. And science is now confirming that Psilocybin is highly effective at treating various addictions and possibly even depression/anxiety, and other psychedelics like MDMA are effective at treating conditions like PTSD. Some recent studies:
7-22-21 - Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Addiction States -
https://www.biorxiv.org/content/10.1101/2021.07.22.453441v1 6-29-21 - Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic -
https://pubmed.ncbi.nlm.nih.gov/34246008/ “We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in Ontario, Canada, during COVID-19 restrictions (from March 2020 - February 2021; n = 107), compared to patients who received treatment in the previous year (March 2019 - February 2020; n = 160). Both groups experienced significant and comparable improvements in depressive symptoms, suicidal ideation, and anxiety with repeated ketamine infusions.”
5-10-21 - MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study -
https://www.nature.com/articles/s41591-021-01336-3In the active group, 88% of participants had a significant reduction in symptoms, and 67% of participants no longer met the criteria for a PTSD diagnosis after the treatments.
5-1-21 - Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial -
https://pubmed.ncbi.nlm.nih.gov/33146667/“Findings suggest that psilocybin with therapy is efficacious in treating MDD, thus extending the results of previous studies of this intervention in patients with cancer and depression and of a nonrandomized study in patients with treatment-resistant depression.”
4-15-21 - Trial of Psilocybin versus Escitalopram for Depression (Imperial College of London) -
https://www.nejm.org/doi/full/10.1056/NEJMoa2032994“A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, −3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons.”
3-5-15 - Psychedelics not linked to mental health problems or suicidal behavior: A population study -
https://pubmed.ncbi.nlm.nih.gov/25744618/ “A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental health. After adjusting for sociodemographics, other drug use and childhood depression, we found no significant associations between lifetime use of psychedelics and increased likelihood of past year serious psychological distress, mental health treatment, suicidal thoughts, suicidal plans and suicide attempt, depression and anxiety. We failed to find evidence that psychedelic use is an independent risk factor for mental health problems. Psychedelics are not known to harm the brain or other body organs or to cause addiction or compulsive use; serious adverse events involving psychedelics are extremely rare. Overall, it is difficult to see how prohibition of psychedelics can be justified as a public health measure.”
9-11-14 - Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction -
https://pubmed.ncbi.nlm.nih.gov/25213996/“Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%).”
7-21-16 - Long-term follow-up of psilocybin-facilitated smoking cessation -
https://pubmed.ncbi.nlm.nih.gov/27441452/ “At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives.”
8-19-13 - Psychedelics and Mental Health: A Population Study -
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0063972“21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems.”
I have an even more expansive collection of research if anyone is interested.
Be safe out there comrades.